[(64)Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model

por Poschenrieder, Andreas, Schottelius, Margret, Osl, Theresa, Schwaiger, Markus, Wester, Hans-Jürgen
Publicado 2017

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency

por Osl, Theresa, Schmidt, Alexander, Schwaiger, Markus, Schottelius, Margret, Wester, Hans-Jürgen
Publicado 2020

First (18)F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo

por Poschenrieder, Andreas, Osl, Theresa, Schottelius, Margret, Hoffmann, Frauke, Wirtz, Martina, Schwaiger, Markus, Wester, Hans-Jürgen
Publicado 2016

Effect of Carbohydration on the Theranostic Tracer PSMA I&T

por Schmidt, Alexander, Wirtz, Martina, Färber, Stefanie Felicitas, Osl, Theresa, Beck, Roswitha, Schottelius, Margret, Schwaiger, Markus, Wester, Hans-Jürgen
Publicado 2018

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent

por Schottelius, Margret, Osl, Theresa, Poschenrieder, Andreas, Hoffmann, Frauke, Beykan, Seval, Hänscheid, Heribert, Schirbel, Andreas, Buck, Andreas K., Kropf, Saskia, Schwaiger, Markus, Keller, Ulrich, Lassmann, Michael, Wester, Hans-Jürgen
Publicado 2017